ClearPoint Neuro adds to gains, up 125% since Sept 23

Clearpoint Neuro

03/10/2025 17:06

** The stock of device and technology company ClearPoint Neuro CLPT.O is up 10% on Friday to $27.40, the highest since February 2021. It has risen 125% since September 23

** The stock jumped after uniQure N.V. QURE.O said before the bell on September 24 that it completed a successful trial of its gene therapy for Huntington's disease. ClearPoint Neuro provides the device for the Dutch biotech firm's gene therapy

** ClearPoint announcedon October 1 the development and demonstration of its proprietary Robotic Neuro-Navigation System

** Lake Street Capital Markets and B. Riley Securities both have a 'buy' rating on CLPT, with a $30 and $28 price target, respectively

** California-based ClearPoint has nearly $800 mln current market cap

(Reporting by Karen Brettell)

((karen.brettell@tr.com))